About Us
CellSpectrum is an Immuneel-sponsored resource committed to supporting healthcare providers (HCPs), patients, and caregivers throughout each step of treatment with our cell therapies.
Who We Are
Immuneel is pioneering cell and gene therapies such as Chimeric Antigen Receptor T cell therapy (CAR-T cell therapy) in India. CAR-T cell therapies use genetically modified human immune cells to fight cancer.
Our mission is to provide innovative and personalized treatment options for patients battling cancer. We are a leading organization dedicated to the development, advancement, and delivery of CAR-T cell therapies, transforming the landscape of oncology.
Our Scientific Advisory Board
Our global outlook, development strategy, and collaborations are enabled by our luminous scientific advisory board which consists of some of the most prominent names in the world of cell and gene therapy. Their stellar track records in research and its translation to life-saving therapies give assurance and heft to our capabilities. We are advised by the best in the field, to bring the best to India.
Prof. Bruce Levine
Ph.D.
A co-inventor of the first FDA approved gene therapy, Prof. Levine has conducted first in-human adoptive immunotherapy trials using CAR-T cells, the first infusions of gene edited cells, the first human use of a lentiviral vector for gene delivery, and the first use of lentivirus modified cells to treat cancer. Prof. Levine holds 27 US patents. He has authored and co-authored >180 manuscripts and book chapters with a Google Scholar citation h-index of 85.
Prof. Carl June
MD
Immunotherapy pioneer and career immunologist. Dr. June is credited with the development of T-cell therapy for cancer (CAR-T). He has published more than 350 manuscripts. He presently leads research in the mechanisms of lymphocyte activation relating to immune tolerance and adoptive immunotherapy for cancer and chronic infection. He has been honored with Dan David Prize Laureate in 2021 , Elected to the National Academy of Sciences in 2020, Elected to the American Academy of Arts and Sciences in 2014, and Elected to the Institute of Medicine in 2012.
Dr Noopur Raje
MD
A translational researcher, Dr. Raje is an authority in the field of multiple myeloma having published extensively towards its research. A member of numerous cancer societies and a reviewer for several scientific journals. Dr. Raje consults with leading pharma companies. She presently leads research in understanding the biology and treatment of multiple myeloma with novel therapeutics. She has been honored with the Claflin Distinguished Scholar Award and Leukemia and Lymphoma Society Clinical Scholar Award.
Vijay Chiruvolu
Ph.D., MBA
A seasoned technical leader with extensive experience in development and manufacturing of recombinant proteins, monoclonal antibodies, gene and cell therapy products. More than 2 decades of leadership responsibilities across various positions in process development, manufacturing and quality at organizations – Scios, Avigen, Hoffmann-La Roche, Johnson & Johnson, Amgen and Kite (a Gilead company). He has been honored as Member of PDA ATMP Advisory Board, Member of PDA Bio Advisory Board and PDA Process Validation Interest Group Leader.
Bala S. Manian
Ph.D.
For four prolific decades, this Silicon Valley member and innovator has founded thriving companies in life science, biotech, and medical technology. Leadership roles at Digital Optics, Quantum Dot Corporation, and SurroMed underline their impact. With expertise in electro-optical systems, they've driven commercial successes, amassing 50+ patents and earning recognition as an innovator and mentor. A 1999 Technical Academy Award recipient, they hold board positions at Equillium Bio and Vaccinex, solidifying their industry influence.
Cutting-Edge Innovation Meets Compassionate Care
India's first Integrated Cell Therapy Development & Manufacturing Facility inauguration (from left to right Dr. Renu Swarup, Dr. Arun Anand, Ms. Kiran M Shaw and Dr. Devi Shetty)
State-of-the-art CGT facility
Inauguration of Immuneel's cGMP. (from left to right) Dr. Arun Anand, Ms. Kiran M Shaw, Dr. Devi Shetty, Dr. Kush Parmar
(from left to right) Dr. Carl H June, Dr. Siddhartha Mukherjee and Dr. Arun Anand attending Immuneel's 1st Science Summit 'celltalk'
Immuneel's integrated multi-product facility
Immuneel team with Dr. Carl H June & Dr. Sharat Damodar at ASH Annual Meeting 2022, USA
Immuneel team with Dr. Noopur Raje
Immuneel with Hospital Clinic Barcelona team at EHA Annual Meeting 2023, Germany
Immuneel presents at Cellicon Valley 23, USA (with Dr. Bruce Levine)
(from left to right) Dr. Carl H June, Dr. Siddhartha Mukherjee and Dr. Bruce Levine at Immuneel's milestone - Cellicon Valley' 23, USA
Immuneel has built end-to-end capabilities and processes including cGMP lentiviral vector manufacturing to assure the delivery of high-quality, cost-effective cell therapy in India, maximizing value and efficiency, scientifically.
Our multi-product, multi-process facilities are designed to be globally compliant with semi-integrated, semi-automated closed-cell manufacturing processes.
Our network of advisors and partners coupled with our team’s diverse experience are key enablers in our path to success in delivering our Smart Cell Therapies.
Our Approach to Make Your Treatment Journey Easy
Revolutionizing cancer treatment through CAR-T cell therapy, focusing on personalized care, scientific excellence, and continuous innovation.
Clinical Trials
Our team actively participates in clinical trials, collaborates with leading research institutions.
Patient Support
Our team actively provides patient support in their personalized treatment journey.
Global Reach
Our team actively participates in collaborating with multiple institutes and global companies.
Do you still have a question?
Don't hesitate to reach out to our experienced team. We're dedicated to providing you with the support and guidance you need on your path to personalized cell and gene therapies. Contact us today for a compassionate and informative conversation.
Contact us